welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
Whole Body Vibration Therapy in Boys With Duchenne Muscular Dystrophy
study id #: NCT01954940
condition: Duchenne Muscular Dystrophy
Whole-body vibration therapy (WBVT) is a novel, non-pharmacological intervention aimed at improving muscle strength and endurance as well as bone density. It holds promise for children with neuromuscular disorders such as Duchenne muscular dystrophy (DMD) since muscle weakness results not only from muscle breakdown but also physical inactivity and muscle disuse atrophy. Weak DMD patients may increasingly limit their physical activity due to fear of falling or loss of independence (e.g. difficulty rising to stand without assistance). Prolonging the length of time boys with DMD are ambulatory is important for delaying complications of this disease (lung hypoventilation, scoliosis) as well as maintaining bone health. We propose to conduct a pilot study of WBVT in young boys with Duchenne muscular dystrophy (DMD). The primary outcome will be to document safety and feasibility of WBVT in this patient population. The secondary outcomes will evaluate changes in muscle strength and endurance. Bone health will also be examined as part of routine clinical care. The study will include 20 ambulatory boys with DMD; patients will be randomized (1:1 allocation) into 2 groups: WBVT treatment or no WBVT treatment (controls). Treatment groups will consist of 10 boys undergoing daily WBVT in an 8-week, open-label trial.
intervention: Whole Body Vibration Therapy
mechanism of action: No pharmaceutical intervention
last updated: November 21, 2018
start date: March 2013
estimated completion: March 2017
phase of development: N/A
size / enrollment: 4
- Assess the safety of using whole body vibration therapy in boys with Duchenne muscular dystrophy. To assess whether whole body vibration therapy can improve muscle strength and prolong ambulation from baseline to 8 weeks of therapy. To asses. [Time Frame: 8 weeks]
Is WBVT safe, convenient and well-tolerated when administered daily to ambulatory to boys with DMD?
- Does WBVT result in any change in muscle strength. [ Time Frame: 8 weeks ]
Does WBVT results in any measurable change in muscle strength measured by the maximum resistance of deltoid, hip flexor and knee extensor (measured with microFET2 dynamometer) and grip strength (measured by Jamar hand-held dynamometer)
- Does WBVT result in any muscle function change. [ Time Frame: 8 weeks ]
Does WBVT results in any measurable change in muscle function as measured by timed functional testing (timed 10m walk test; timed 4-stair climb; timed Gower manoeuvre, 6-minute walk test)?
- Does WBVT result in any measurable change in muscle endurance. [ Time Frame: 8 weeks ]
Does WBVT result in any measurable change in muscle endurance (total number of steps taken each day, measured by pedometer)?
- Quality of life changes. [ Time Frame: 8 weeks ]
Does WBVT result in any change in patient and family reported quality of life report? Measured by the Peds Q of L questionnaire.
- Gait changes. [ Time Frame: 8 weeks ]
Does WBVT result in any change in patient's gait (as measured by Gangway gait analysis and Leonardo force plate analysis)
- Bone health [ Time Frame: 8 weeks ]
Does WBVT result in any change in bone health indices (as measured by pQCT and routine skeletal imaging)
• Diagnosis of Duchenne muscular dystrophy confirmed by at least one of the following:
- Dystrophin immunofluorescence and/or immunoblot showing complete dystrophin deficiency, and clinical presentation consistent with typical DMD
- Positive gene deletion test (missing one or more exons) in the central rod domain (exons 25-60) of dystrophin, where reading frame can be predicted as "out-of-frame", and clinical presentation consistent with typical DMD
- Complete dystrophin gene sequencing showing an alteration (point mutation, duplication, or other mutation resulting in a stop codon mutation) definitively associated with DMD, and clinical presentation consistent with typical DMD
• Age between 5 - 14 yrs old (inclusive)
• Positive Gower sign (indicating ability to rise from the floor & presence of proximal muscle weakness).
• Able to walk 10 meters in <12 seconds
• Able to stand upon WBVT plate (with knees flexed) for entire treatment protocol (i.e. 15-minutes)
• Stable absolute dose of glucocorticoids (i.e. prednisone or deflazacort) for at least 3 months prior
• Stable absolute doses of all medication that may affect muscle function (i.e. coenzyme Q10, green tea extract, creatine, arginine, glutamine, nutritional supplements, etc.) for at least 3 months prior
• Stable absolute dose of all medication that may affect bone metabolism (i.e. vitamin D and calcium supplementation) for at least 3 months prior
• Clinical presentation, genetic testing and/or muscle biopsy consistent with Becker muscular dystrophy
• History of recent surgery (within past 6-months)
• History of a recent fracture (long-bone or vertebral) within past 6-months.
• Acute inflammatory processes of lower extremities (e.g. cellulitis, etc) due to risk of pain and/or worsening inflammatory process
• History of venous thrombosis (theoretically risk of inducing thromboembolic event).
• History of kidney or bladder stones
• History of uncontrolled seizures or severe migraines
• History of cardiac arrhythmia
• Intracranial pathology or hardware (e.g. ventriculoperitoneal shunt, cochlear implant).
• Use of any investigational or experimental products within last 6-months and/or concomitant participation in another study
• Inability or refusal to follow the study requirements (e.g. autism, severe cognitive or behaviour problems)
• Inability or refusal to provide informed consent (parent) and/or assent (child)
A Study of the Safety, Tolerability & Efficacy of Long-term Administration of Drisapersen in US & Canadian S...This is a phase III, multicenter, open-l...
Duchenne Muscular Dystrophy Clinical TrialThe primary objective of this investigat...
PTC Therapeutics Receives FDA Approval for the Expansion of the EMFLAZA® (deflazacort) Labeling to Include Patients...PTC Therapeutics, Inc. today announced t...
Clinical Intramuscular Gene Transfer Trial of rAAVrh74.MCK.Micro-Dystrophin to Patients With Duchenne Muscular Dystr...The proposed phase I clinical trial is a...
Sodium Nitrate to Improve Blood FlowInvestigators recently showed that tadal...
A Phase IIa Study of TAS-205 for Duchenne Muscular DystrophyThe objective of this study is to evalua...
A Phase III Double-blind Study With Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Taking Glucocortico...The purpose of the study is to assess th...
Sarepta Therapeutics to Provide Update on Duchenne Muscular Dystrophy Gene Therapy ProgramSarepta Therapeutics, Inc., the leader i...
DMD HUB: Expanding clinical trial capacity for Duchenne muscular dystrophy in the UKWith Duchenne muscular dystrophy (DMD) c...
Sarepta Announces Clinical Hold Lifted for its Duchenne Muscular Dystrophy Micro-dystrophin Gene Therapy ProgramSarepta Therapeutics, Inc., a commercial...
Capricor to Meet with FDA under its RMAT Designation to Discuss HOPE-2 Clinical TrialCapricor Therapeutics announced today th...